
Avillion hires Lundbeck chief executive
pharmafile | June 16, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Avillion, Lundbeck, wiinberg
UK drug development firm Avillion has appointed Lundbeck chief executive Ulf Wiinberg as the chairman of its board of directors.
Wiinberg has been the chief executive of Denmark-heaquartered Lundbeck since June 2008. Prior to this position he worked at Wyeth/Lederle for 27 years, most recently as president of Wyeth Europe and Wyeth BioPharma.
Wiinberg also sits on the boards at the European Federation of Pharmaceutical Industries and Associations (EFPIA); the International Federation of Pharmaceutical Manufacturer Association (IFPMA); and the Pharmaceutical Research and Manufacturers of America (PhRMA).
In Denmark Wiinberg also serves on the Industrial Policy Committee under the Confederation of Danish Industry, and he is a member of the board of directors of Alfa Laval, a large public company in Sweden.
Genghis Lloyd-Harris, a non-executive director of Avillion and a partner at Abingworth LLP, says: “On behalf of the board of directors, I am pleased to welcome Ulf as Avillion’s chairman.”
Wiinberg adds: “I am delighted to join the company as chairman and look forward to supporting its further growth and development.”
Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug
Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …

Lundbeck to restructure R&D, shedding up to 160 jobs
Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research …

Lundbeck’s Vyepti secures US approval for migraine prevention
Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention …






